Average ratings

Recent Reviews


Be the first to review Acomplia

 

Profile

Acomplia (rimonabant) was the first in a new class of therapeutic agents called Cannabinoid-1 Receptor Blockers (CB1). Acomplia was studied for use in the treatment of obesity and related conditions.

Resources

Short link to review Acomplia: http://iwgc.net/e6nk